search
Back to results

The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Colesevelam HCl
Sitagliptin
Sponsored by
KineMed
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Colesevelam, type 2 diabetes, sitagliptin, glucose metabolism

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or Female
  • Females of childbearing potential are on approved birth control method
  • Negative pregnancy testing for females of childbearing potential
  • Previously diagnosed or newly diagnosed with T2DM drug naïve subjects
  • HbA1c: 6.7-10%
  • Age 18 - 80 years
  • BMI ≥ 18.5 kg/m2 and ≤ 40 kg/m2
  • Fasting serum glucose < 300 mg/dL
  • Normal liver function, normal thyroid function, no history of liver, biliary or intestinal disease
  • Normal TSH
  • On stable diet and exercise routine for at least 4 weeks prior to screening
  • Has had a stable weight (+/-5%) for ≥3 months before screening

Exclusion Criteria:

  • A history of type 1 diabetes mellitus or history of diabetic ketoacidosis
  • History of chronic (required daily for > 2 months) use of insulin therapy
  • Treatment with blood pressure lowering therapy that has not been stable for three months before screening
  • Treatment with lipid lowering medication other than statins
  • Treatment with statins that has not been stable for three months before screening
  • Treatment with a DPP-4 inhibitor or and GLP1 agonists at any time
  • Treatment with a thiazolidinedione (TZD) within the last 6 months of screening
  • History of an allergic or toxic reaction to sitagliptin or colesevelam
  • History of dysphagia, swallowing disorders, bowel obstruction, intestinal motility disorder, and gastrointestinal disorders
  • History of major gastrointestinal surgery
  • History of kidney problems
  • Fasting plasma triglycerides > 300 mg/dL
  • Serum LDL-C <60 mg/dL
  • Positive toxicology test
  • Known hypersensitivity to colesevelam HCl or sitagliptin.
  • Any contraindications to a study medication (colesevelam HCl or sitagliptin).

Sites / Locations

  • University of California, San Francisco
  • Clinical Pharmacology of Miami
  • Healthcare Discoveries, LLC d/b/a ICON Development Solutions

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Colesevelam HCl: 3 tablets, 2x/day

Colesevelam plus Sitagliptin

Arm Description

Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.

Colesevelam: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks. Sitagliptin: Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.

Outcomes

Primary Outcome Measures

Hemoglobin A1C
Change from baseline in hemoglobin A1C after 12 weeks of colesevelam or colesevelam plus sitagliptin treatments
Fasting Plasma Glucose
Change from baseline in fasting plasma glucose concentrations after 12 weeks of colesevelam or colesevelam plus sitagliptin treatments.
Fasting Endogenous Glucose Production
Change from baseline in fasting endogenous glucose production after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment
Fasting Gluconeogenesis
Change from baseline in fasting gluconeogenesis after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment
Fasting Glycogenolysis
Change from baseline in fasting glycogenolysis after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment
Fasting Plasma Glucose Clearance
Change from baseline in fasting plasma glucose clearance after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments.
Appearance Rate of Oral Glucose
Change from baseline in appearance rate of oral glucose after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments
Postprandial Endogenous Glucose Production
Change from baseline in postprandial endogenous glucose production after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments Mean value was calculated using all results measured between 10 and 300 min post meal.
Postprandial Rate of Total Glucose Disposal Area Under the Curve (AUC)
Change from baseline in postprandial rate of total glucose disposal (AUC) after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments AUC was calculated by the trapezoid method using all results measured between 0 and 300 min during the meal tolerance test.
Whole-body Glycolytic Disposal of Oral Glucose
Change in baseline in whole-body glycolytic disposal of oral glucose after 12 weeks of colesevelam alone or colesevelam plus glucose treatments
Postprandial Glucose (AUC)
Comparison between baseline and 12 weeks values of postrandial glucose (AUC).

Secondary Outcome Measures

Fasting Plasma C-peptide
To evaluate the effect of treatments on plamsa C-peptide concentrations.
Fasting Plamsa Glucagon
To evaluate the effect of treatments on plasma glucagon concentrations.
Fasting Active Plasma Glucagon Like-Peptide 1 (GLP-1)
To evaluate the effect of treatments on plasma GLP-1 concentrations.
Fasting Plasma Total Glucose-dependent Insulinotropic Peptide (GIP)
To evaluate the effect of treatments on plasma Glucose-dependent Insulinotropic Peptide (GIP) concentrations.
Fasting Insulin
To evaluate the effect of treatments on fasting insulin concentrations
Postprandial Insulin (AUC)
To evaluate the effect of treatments on postprandial insulin (AUC)
Postprandial C-peptide (AUC)
To evaluate the effect of treatments on postprandial C-peptide (AUC)
Postprandial Active GLP-1 (AUC)
To evaluate the effects of treatments on postprandial active GLP-1 (AUC)
Postprandial Total GIP (AUC)
To evaluate the effects of treatment on postprandial total GIP (AUC)
Postprandial Glucagon (AUC)
To evaluate the effects of treatment on postprandial glucagon (AUC)

Full Information

First Posted
March 23, 2010
Last Updated
January 15, 2013
Sponsor
KineMed
search

1. Study Identification

Unique Protocol Identification Number
NCT01092663
Brief Title
The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus
Official Title
The Effects of Co-administration of Colesevelam and Sitagliptin on Glucose Metabolism in Patients With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
January 2013
Overall Recruitment Status
Completed
Study Start Date
March 2010 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
July 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
KineMed

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will assess the effects of colesevelam, alone or in combination with sitagliptin, on glucose metabolism in subjects with T2DM inadequately controlled by diet and exercise
Detailed Description
The hypothesis is that co-administrationof colesevelam plus sitagliptin results in a greater reduction in HbA1c compared to colesevelam HCl treatment by improving the effects of colesevelam on fasting glucose metabolism improving the effects of colsevelam on postprandial glucose metabolism

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Colesevelam, type 2 diabetes, sitagliptin, glucose metabolism

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
61 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Colesevelam HCl: 3 tablets, 2x/day
Arm Type
Active Comparator
Arm Description
Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
Arm Title
Colesevelam plus Sitagliptin
Arm Type
Active Comparator
Arm Description
Colesevelam: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks. Sitagliptin: Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
Intervention Type
Drug
Intervention Name(s)
Colesevelam HCl
Other Intervention Name(s)
Welchol
Intervention Description
Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
Intervention Type
Drug
Intervention Name(s)
Sitagliptin
Other Intervention Name(s)
Januvia
Intervention Description
Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
Primary Outcome Measure Information:
Title
Hemoglobin A1C
Description
Change from baseline in hemoglobin A1C after 12 weeks of colesevelam or colesevelam plus sitagliptin treatments
Time Frame
Baseline and 12 weeks
Title
Fasting Plasma Glucose
Description
Change from baseline in fasting plasma glucose concentrations after 12 weeks of colesevelam or colesevelam plus sitagliptin treatments.
Time Frame
Baseline and 12 weeks
Title
Fasting Endogenous Glucose Production
Description
Change from baseline in fasting endogenous glucose production after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment
Time Frame
baseline and 12 weeks
Title
Fasting Gluconeogenesis
Description
Change from baseline in fasting gluconeogenesis after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment
Time Frame
baseline and 12 weeks
Title
Fasting Glycogenolysis
Description
Change from baseline in fasting glycogenolysis after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment
Time Frame
baseline and 12 weeks
Title
Fasting Plasma Glucose Clearance
Description
Change from baseline in fasting plasma glucose clearance after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments.
Time Frame
baseline and 12 weeks
Title
Appearance Rate of Oral Glucose
Description
Change from baseline in appearance rate of oral glucose after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments
Time Frame
baseline and 12 weeks
Title
Postprandial Endogenous Glucose Production
Description
Change from baseline in postprandial endogenous glucose production after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments Mean value was calculated using all results measured between 10 and 300 min post meal.
Time Frame
baseline and 12 weeks
Title
Postprandial Rate of Total Glucose Disposal Area Under the Curve (AUC)
Description
Change from baseline in postprandial rate of total glucose disposal (AUC) after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments AUC was calculated by the trapezoid method using all results measured between 0 and 300 min during the meal tolerance test.
Time Frame
baseline and 12 weeks
Title
Whole-body Glycolytic Disposal of Oral Glucose
Description
Change in baseline in whole-body glycolytic disposal of oral glucose after 12 weeks of colesevelam alone or colesevelam plus glucose treatments
Time Frame
baseline and 12 weeks
Title
Postprandial Glucose (AUC)
Description
Comparison between baseline and 12 weeks values of postrandial glucose (AUC).
Time Frame
Baseline and 12 weeks
Secondary Outcome Measure Information:
Title
Fasting Plasma C-peptide
Description
To evaluate the effect of treatments on plamsa C-peptide concentrations.
Time Frame
Baseline and 12 weeks
Title
Fasting Plamsa Glucagon
Description
To evaluate the effect of treatments on plasma glucagon concentrations.
Time Frame
Baseline and 12 weeks
Title
Fasting Active Plasma Glucagon Like-Peptide 1 (GLP-1)
Description
To evaluate the effect of treatments on plasma GLP-1 concentrations.
Time Frame
Baseline and 12 weeks
Title
Fasting Plasma Total Glucose-dependent Insulinotropic Peptide (GIP)
Description
To evaluate the effect of treatments on plasma Glucose-dependent Insulinotropic Peptide (GIP) concentrations.
Time Frame
Baseline and 12 weeks
Title
Fasting Insulin
Description
To evaluate the effect of treatments on fasting insulin concentrations
Time Frame
Baseline and 12 weeks
Title
Postprandial Insulin (AUC)
Description
To evaluate the effect of treatments on postprandial insulin (AUC)
Time Frame
Baseline and 12 weeks
Title
Postprandial C-peptide (AUC)
Description
To evaluate the effect of treatments on postprandial C-peptide (AUC)
Time Frame
Baseline and 12 weeks
Title
Postprandial Active GLP-1 (AUC)
Description
To evaluate the effects of treatments on postprandial active GLP-1 (AUC)
Time Frame
Baseline and 12 weeks
Title
Postprandial Total GIP (AUC)
Description
To evaluate the effects of treatment on postprandial total GIP (AUC)
Time Frame
Baseline and 12 weeks
Title
Postprandial Glucagon (AUC)
Description
To evaluate the effects of treatment on postprandial glucagon (AUC)
Time Frame
Baseline and 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or Female Females of childbearing potential are on approved birth control method Negative pregnancy testing for females of childbearing potential Previously diagnosed or newly diagnosed with T2DM drug naïve subjects HbA1c: 6.7-10% Age 18 - 80 years BMI ≥ 18.5 kg/m2 and ≤ 40 kg/m2 Fasting serum glucose < 300 mg/dL Normal liver function, normal thyroid function, no history of liver, biliary or intestinal disease Normal TSH On stable diet and exercise routine for at least 4 weeks prior to screening Has had a stable weight (+/-5%) for ≥3 months before screening Exclusion Criteria: A history of type 1 diabetes mellitus or history of diabetic ketoacidosis History of chronic (required daily for > 2 months) use of insulin therapy Treatment with blood pressure lowering therapy that has not been stable for three months before screening Treatment with lipid lowering medication other than statins Treatment with statins that has not been stable for three months before screening Treatment with a DPP-4 inhibitor or and GLP1 agonists at any time Treatment with a thiazolidinedione (TZD) within the last 6 months of screening History of an allergic or toxic reaction to sitagliptin or colesevelam History of dysphagia, swallowing disorders, bowel obstruction, intestinal motility disorder, and gastrointestinal disorders History of major gastrointestinal surgery History of kidney problems Fasting plasma triglycerides > 300 mg/dL Serum LDL-C <60 mg/dL Positive toxicology test Known hypersensitivity to colesevelam HCl or sitagliptin. Any contraindications to a study medication (colesevelam HCl or sitagliptin).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carine Beysen, DPhil
Organizational Affiliation
KineMed, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94110
Country
United States
Facility Name
Clinical Pharmacology of Miami
City
Miami
State/Province
Florida
ZIP/Postal Code
33014
Country
United States
Facility Name
Healthcare Discoveries, LLC d/b/a ICON Development Solutions
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78209
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
17379048
Citation
Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007 Jan;29(1):74-83. doi: 10.1016/j.clinthera.2007.01.003.
Results Reference
background
PubMed Identifier
18852398
Citation
Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008 Oct 13;168(18):1975-83. doi: 10.1001/archinte.168.18.1975.
Results Reference
background
PubMed Identifier
18458145
Citation
Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008 Aug;31(8):1479-84. doi: 10.2337/dc08-0283. Epub 2008 May 5.
Results Reference
background
PubMed Identifier
18663165
Citation
Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008 Jul 28;168(14):1531-40. doi: 10.1001/archinte.168.14.1531.
Results Reference
background
PubMed Identifier
17130196
Citation
Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006 Dec;29(12):2632-7. doi: 10.2337/dc06-0703.
Results Reference
background
PubMed Identifier
17300595
Citation
Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007 Mar;9(2):194-205. doi: 10.1111/j.1463-1326.2006.00704.x.
Results Reference
background
PubMed Identifier
17485570
Citation
Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007 Aug;30(8):1979-87. doi: 10.2337/dc07-0627. Epub 2007 May 7. Erratum In: Diabetes Care. 2008 Aug;31(8):1713.
Results Reference
background
Links:
URL
http://www.ich.org/
Description
Ethics and Compliance

Learn more about this trial

The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs